Exactech and Bodycad Sign Exclusive Distribution Agreement – To Offer Personalized Unicompartmental Knee Replacement

November 24, 2020

Exactech announced today the signing of an exclusive distribution agreement with orthopaedic manufacturer Bodycad for its Reflex Uni™ knee in the U.S.

This new product offering expands Exactech’s Truliant® primary and revision knee system to include a personalized unicompartmental implant that is designed to fit each patient’s unique anatomy. Truliant Reflex Uni is the latest addition to Exactech’s Active Intelligence® technology platform of personalized, data-driven solutions designed to improve patient outcomes.

Leveraging the latest in 3D printing technology, Truliant Reflex Uni was developed by Bodycad using a proprietary software algorithm and a fully integrated production system. Bodycad has developed an innovative 3D image rendering, digital planning, and production system to optimize personalized restoration of each patient’s anatomy. Bodycad’s proprietary software serves as the digital backbone to highly automate all processes.

The resulting patient-specific unicompartmental knee replacement requires no off-the-shelf implants and minimal instrumentation, making it ideally suited for an efficient hospital or ambulatory surgery center. In addition, Truliant Reflex Uni offers patients a better fit and potential for improved clinical results and satisfaction.

“Innovation in unicompartmental knee implants has been stagnant for years,” said John McDaniel, Exactech’s Senior Vice President, Large Joints. “We intentionally delayed offering a partial knee until we had something that could address the shortcomings of existing designs. With Truliant Reflex Uni, surgeons have the option to change implant design and placement to meet the needs of each patient. We’re excited about this personalized solution and its potential to maximize bone coverage, achieve proper alignment, and optimize joint function.”

“Bodycad’s indisputable expertise in the computer design of personalized unicompartmental prostheses united with the knowledgeable US sales force of Exactech is a union which will allow us to raise the success of a personalized joint restoration,” said CEO and Founder of Bodycad Jean Robichaud.

The Truliant Knee System is an award-winning platform of implants, instruments and technology that helps surgeons achieve reproducibility and efficiency in primary and revision knee arthroplasty. Exactech’s Active Intelligence portfolio connects surgeons and patients with smart decisions throughout the journey of care.

SourceExactech

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”